Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

The most frequent <i>BCR-ABL1</i>-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that <i>BCR-ABL1</i> transcript types confer different...

Full description

Bibliographic Details
Main Authors: Sílvia Marcé, Blanca Xicoy, Olga García, Marta Cabezón, Natalia Estrada, Patricia Vélez, Concepción Boqué, Miguel Sagüés, Anna Angona, Raúl Teruel-Montoya, Francisca Ferrer-Marín, Paula Amat, Juan Carlos Hernández-Boluda, Mariana M. Ibarra, Eduardo Anguita, Montserrat Cortés, Andrés Fernández-Ruiz, Sandra Fontanals, Lurdes Zamora, on behalf of the Grupo Español de Leucemia Mieloide Crónica (GELMC)
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Clinical Medicine
Subjects:
chronic myeloid leukemia
<i>BCR</i><i>-ABL1</i> transcripts
response to imatinib
survival
discontinuation
relapse-free survival
Online Access:https://www.mdpi.com/2077-0383/10/14/3146

Internet

https://www.mdpi.com/2077-0383/10/14/3146

Similar Items